

Supplemental materials

Five major targets in the health-care reform plan in China in 2009

1. Medical insurance: expand basic medical insurance programs to cover more than 90% of Chinese people.
2. Drug supply security: Establish a national system for essential drugs to meet the basic need for treatment and prevention of diseases and to ensure safety, quality, and supply.
3. Medical service provision: Develop a primary healthcare service to improve the medical care and public health service system at grassroots level.
4. Public health service: Provide equal access to urban and rural dwellers.
5. Reform in public hospitals to increase in public investment, restructure the hospital management system, and correct the tendency for commercialisation.

Major categories of data and Key variables

A. Demographic:

Gender, Age, Ethnicity, Education Level, Medical Insurance, Occupation, Others

B. Medical History:

Diabetes Mellitus, Hypertension, Dyslipidemia, Stroke History, Heart Disease History (Coronary Atherosclerotic Heart Disease, Heart Failure, Atrial Fibrillation, others), Others

C. Medications History:

Antiplatelet Agents, Anticoagulant Agents, Lipid-modifying Agents, Hypoglycemic Agents, Antihypertensive Agents, Others

D. In-hospital Examination

Blood test: Total Cholesterol (CHO), Triglyceride(TG), High Density Lipoprotein(HDL), Low Density Lipoprotein(LDL), Fasting Plasma Glucose(FPG), Hemoglobin A1c, Homocysteine (HCY), Serum Creatinine, Serum Urea Nitrogen, INR, Uric Acid, White Blood Cell, Platelet, High-sensitivity C-reactive Protein, C-reactive Protein, Others

E. Imaging Evaluation

Head CT, Head MRI, TCD (Transcranial Doppler, CTA (CT Angiography, MRA (Magnetic Resonance Angiography) , DSA (Digital Subtraction Angiography) , Transthoracic Echocardiography, Transesophageal Echocardiography, 24-hour Dynamic Blood Pressure Monitoring, 24-hour Dynamic Electrocardiogram, TCD Foaming Test, Others

F. In-hospital Interventions and Complications

IV Thrombolytic Therapy, Antiplatelet / Antithrombotic Therapy, Anticoagulant Therapy, Lipid- modifying Therapy, Antihyperglycemic Therapy, Antihypertensive Therapy, Administered Traditional Chinese Drugs, Others

Administered Vascular Related Procedures and Surgical Treatment (Carotid Artery Stenting/ Carotid Endarterectomy (CEA)/ Intracranial Artery Stenting/ Decompressive

Hemicraniectomy), Administered Carotid Artery Stenting, Administered Carotid Endarterectomy (CEA), Administered Intracranial Artery Stenting, Administered Decompressive Hemicraniectomy, Others

Swallow function assessment, DVT Prophylaxis, Rehabilitation Evaluation, Others

G. In-hospital Complications

Neurological Complications, Other Complications: Pulmonary Embolism, Atrial Fibrillation, Urinary Tract Infections, Cardiac and/or Pulmonary Arrest, Myocardial Infarction, Pneumonia, Others

H. Discharge Information

Status at discharge (Death, Survival), Discharge Date, The Length of Stay, Hospital Expenditure (RBM), Medicine Expenditure (RBM), Discharge Way, Discharge Destination, Others

Discharge Medication: Antiplatelet Agents, Anticoagulant Therapy, Lipid- modifying Therapy, Antihyperglycemic Therapy, Antihyperglycemic Therapy, Stroke Education or Lifestyle Interventions, Others

Others